Nasdaq
$22.66▲ 1.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.54BShares out 68.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 10.16Regular26.10.17 03:01SCHEDULE 13G/AOwnership#●●●#●●●
uniQure N.V.
JPMorgan Chase & Co. has filed a SCHEDULE 13G/A amendment regarding its beneficial ownership in uniQure N.V. This filing serves to update the status of the reporting entity's significant equity position in the company.…more
$22.66+1.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 22:058-KKey event
uniQure N.V.
uniQure announced updated 36-month and 48-month data from its ongoing Phase I/II clinical trials of AMT-130 for Huntington's disease, demonstrating meaningful slowing of disease progression. In the high-dose cohort, the treatment showed an 80% slowing of disease progression based on cUHDRS and 67% based on TFC at 36 months, with sustained therapeutic effects and dose-dependent responses observed through 48 months.…more
$22.66+1.14%vs prev closeView filingShare - 9.2Pre-market26.09.02 20:068-KKey event
uniQure N.V.
On September 2, 2026, uniQure submitted a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorisation Application (MAA) to the U.K. MHRA for its Huntington's disease gene therapy candidate, ifezuntirgene inilparvovec (AMT-130). The submissions are supported by three-year data from the Phase I/II clinical study, and the company has requested priority review from the FDA.…more
$22.66+1.14%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29Regular26.09.29 23:28Bullish#●●●#●●●
uniQure Shares Plummet Following Mixed Huntington's Disease Clinical Data…more
uniQure stock fell after reporting mixed long-term clinical results for its Huntington's disease gene therapy. While 36-month data showed promise, the 48-month outcomes lacked statistical significance, raising concerns among investors.…more
$22.66+1.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29Pre-market26.09.29 20:12
●●●●●●●● ●●●●● ●●●●●●
uniQure announced updated Phase I/II data showing continued slowing of disease progression in Huntington's disease patients treated with its gene therapy candidate. Investors should remain cautious as the results rely on comparisons with external controls and require further regulatory validation.…more
$22.66+1.14%vs prev close - 9.2Regular26.09.03 03:23
●●●●●●●● ●●●●● ●●●●●●
uniQure has submitted its Biologics License Application to the FDA for its Huntington's disease gene therapy, AMT-130. Analyst Sami Corwin views the submission as a positive catalyst for the stock, maintaining an outperform rating with a $73 price target.…more
$22.66+1.14%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report